The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1329
January 11, 2010
View Complete Issue         Table of Contents 2019 
Telavancin (Vibativ) for Gram-Positive Skin Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Telavancin (Vibativ) for Gram-Positive Skin Infections
January 11, 2010 (Issue: 1329)
Telavancin (Vibativ - Astellas and Theravance), a lipoglycopeptide derivative of vancomycin (Vancocin, and others), has received FDA approval for treatment of complicated skin and skin structure infections caused by susceptible gram-positive bacteria...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Telavancin (Vibativ) for Gram-Positive Skin Infections
Article code: 1329a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.